Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: A randomized, open-label, two-period, comparative crossover study

Clinical Therapeutics

Volumn 26, Issue 12, 2004, Pages 2092-2101

  Park, Ji Young ^a   Kim, Kyoung Ah ^a   Park, Pil Whan ^a   Suh, Kwee Hyun ^b   Lee, Gwan Sun ^b  

^a Gachon University College of Medicine   (South Korea)

^b Hanmi Pharmaceutical Co Ltd   (South Korea)

Author keywords

Antiobesity drug; Bioavailability; Desmethylsibutramine (BTS 54 354); Didesmethylsibutramine (BTS 54 505); Pharmaceutical salts; Salt forming drug; Sibutramine

Indexed keywords

1 AMINO 1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYLBUTANE; 1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYL 1 METHYLAMINOBUTANE; DRUG METABOLITE; MESYLIC ACID DERIVATIVE; SIBUTRAMINE; SIBUTRAMINE MESYLATE; UNCLASSIFIED DRUG;

ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; ELECTROCARDIOGRAPHY; HEMATOLOGY; HUMAN; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; URINALYSIS;

EID: 14844347968     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.12.012     Document Type: Article

References (39)

1. Flegal KM, Carroll MD, Ogden CL, and Johnson CL Prevalence and trends in obesity among US adults, 1999-2000 JAMA 288 2002 1723 1727
2. Working Group on the Evaluation of Cancer-Preventive Agents International Agency for Research on Cancer, and World Health Organization Weight Control and Physical Activity Vainio H Bianchini F IARC Handbooks of Cancer Prevention vol 6 2002 IARC Press Montvale, NJ
3. Popkin BM The nutrition transition and its health implications in lower-income countries Public Health Nutr 1 1998 5 21
4. World Health Organization Obesity: Preventing and managing the global epidemic. Report of a WHO consultation on obesity World Health Organ Tech Rep Ser 894 2000 1 253
5. World Health Organization, International Association for the Study of Obesity International Obesity TaskForce The Asia--Pacific Perspective: Redefining Obesity and Its Treatment 2000 Health Communications Australia Lyon, France
6. Rippe JM, Crossley S, and Ringer R Obesity as a chronic disease: Modern medical and lifestyle management J Am Diet Assoc 98 Suppl 2 1998 S9 S15
7. Leung WY, Neil Thomas G, Chan JC, and Tomlinson B Weight management and current options in pharmacotherapy: Orlistat and sibutramine Clin Ther 25 2003 58 80
8. Halpern A, and Mancini MC Treatment of obesity: An update on anti-obesity medications Obes Rev 4 2003 25 42
9. Clapham JC, Arch JR, and Tadayyon M Anti-obesity drugs: A critical review of current therapies and future opportunities Pharmacol Ther 89 2001 81 121
10. Carek PJ, and Dickerson LM Current concepts in the pharmacological management of obesity Drugs 57 1999 883 904
11. Scheen AJ, and Lefebvre PJ Pharmacological treatment of obesity: Present status Int J Obes Relat Metab Disord 23 Suppl 1 1999 47 53
12. Available at Center for Drug Evaluation and Research, and US Food and Drug Administration Phenylpropanolamine (PPA) information pqt3 Accessed May 15, 2003
13. Available at Committee on Safety in Medicines, and Medicines Control Agency Important safety message: European withdrawal of anorectic agents/appetite suppressants: New legal developments, no new safety issues: Licences for phentermine and amfepramone being withdrawn May 2001 Accessed May 15, 2003
14. Jackson HC, Bearham MC, and Hutchins LJ Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat Br J Pharmacol 121 1997 1618
15. Cheetham SC, Viggers JA, Slater NA, and Buckett WR Inhibition of [3H]paroxetine binding by sibutramine, its metabolites and other antidepressants correlates with inhibition of [3H]5-hydroxytryptamine uptake Br J Pharmacol 101 1990 515P
16. 3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments Neuropharmacology 35 1996 63 70
17. Connoley IP, Liu YL, and Frost I Thermogenic effects of sibutramine and its metabolites Br J Pharmacol 126 1999 1487 1495
18. McNeely W, and Goa KL Sibutramine. A review of its contribution to the management of obesity Drugs 56 1998 1093 1124
19. Jackson HC, Needham AM, and Hutchins LJ Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat Br J Pharmacol 121 1997 1758 1762
20. Stricker-Krongrad A, Souquet AM, Jackson HC, and Burlet C Effect of various monoamine receptor antagonists on the decrease in food intake induced by sibutramine in the rat Br J Pharmacol 117 1996 167P
21. Liu YL, Kashani SM, Heal DJ, and Stock MJ Effect of sibutramine on tissue glucose utilisation in the rat Br J Pharmacol 117 1996 324P
22. Hind ID, Mangham JE, and Ghani SP Sibutramine pharmacokinetics in young and elderly healthy subjects Eur J Clin Pharmacol 54 1999 847 849
23. 3H]5-HT uptake: Effect of administration of various antidepressant treatments Neuropharmacology 32 1993 737 743
24. Wickersham RM Novak KK Sibutramine hydrochloride 57th ed Drug Facts and Comparisons 2003 Wolters Kluwer Health Sydney 856 859
25. Davies G Changing the salt, changing the drug Pharm J 266 2001 322 323
26. Berge SM, Bighley LD, and Monkhouse DC Pharmaceutical salts J Pharm Sci 66 1977 1 19
27. Lloyd J, and Raven A Phase I studies and pharmacokinetics 2nd ed. ACPRI Handbook of Clinical Research 1994 Churchill Livingstone St Louis, Mo 114 153
28. Chen J, Lu W, Zhang Q, and Jiang X Determination of the active metabolite of sibutramine by liquid chromatography--electrospray ionization tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 785 2003 197 203
29. Schuirmann DJ A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability J Pharmacokinet Biopharm 15 1987 657 680
30. Available at Center for Drug Evaluation and Research, and US Food and Drug Administration Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products--General Considerations Accessed May 15, 2003
31. Available at US Food and Drug Administration Approved Drug Products with Therapeutic Equivalence Evaluations Accessed March 18, 2003
32. Farolfi M, Powers JD, and Rescigno A On the determination of bioequivalence Pharmacol Res 39 1999 1 4
33. Shargel L, and Yu AB Bioavailability and bioequivalence 4th ed Applied Biopharmaceutics and Pharmacokinetics 1999 Appleton & Lange London 247 279
34. Park JY, Kim KA, and Lee GS Randomized, open-label two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects Clin Ther 26 2004 715 723
35. Meredith P Bioequivalence and other unresolved issues in genetic drug substitution Clin Ther 25 2003 2875 2890
36. Available at Center for Drug Evaluation and Research, and US Food and Drug Administration Guidance for Industry: Statistical Approaches to Establishing Bioequivalence Accessed May 15, 2003
37. Available at Joint Efficacy and Quality Working Group Committee for Proprietary Medicinal Products, and European Agency for the Evaluation of Medicinal Products Note for Guidance on the Investigation of Bioavailability and Bioequivalence Accessed May 15, 2003
38. Cheymol G Clinical pharmacokinetics of drugs in obesity. An update Clin Pharmacokinet 25 1993 103 114
39. Forbes GB, and Welle SL Lean body mass in obesity Int J Obes 7 1983 99 107